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of the many other cellular signaling proteins with which
it interacts (Wajant and Scheurich, 2001).
Mature resting B cells constitutively express recep-
tors for the TNF-L superfamily molecules CD40L and
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activation and maturation, respectively. CD40L ex-Newtown, NSW 2042
pressed on activated T-helper cells binds B cell surfaceAustralia
CD40 and activates signals critical for T cell-dependent
B cell proliferation and production of class-switched
antibodies (Bishop and Hostager, 2003). BAFF is ex-Summary
pressed constitutively in vivo and is required for the
generation of mature long-lived B cells (Schiemann etTo examine the role of the TNF-R superfamily signaling
al., 2001; Thompson et al., 2001). Transgenic overex-protein TRAF2 in mature B cell development and NF-
pression of BAFF leads to increased numbers of matureB activation, conditionally TRAF2-deficient mice
peripheral B cells, particularly in the splenic marginalwere produced. B cells lacking TRAF2 expression in
zone (MZ) and lymph nodes (Khare et al., 2000; Mackaythese mice possessed a selective survival advantage,
et al., 1999). BAFF functions as a survival and maturationaccumulated in the lymph nodes and splenic marginal
factor through its binding to the TNF-R moleculezone, were larger in size, and expressed increased
BAFF-R, while a second BAFF receptor, TACI, antago-levels of CD21/35. These TRAF2-deficient B cells could
nizes this activity (Schiemann et al., 2001; Yan et al.,not proliferate or activate the canonical NF-B path-
2001). CD40, BAFF-R, and TACI all recruit one or moreway in response to CD40 ligation. By contrast, nonca-
species of TRAF to their cytoplasmic domains (Aggar-nonical NF-B activation was constitutively hyperac-
wal, 2003), indicating a central role for these moleculestive, with TRAF2-deficient B cells exhibiting close to
in CD40L and BAFF signaling.maximal processing of NF-B2 from p100 to p52 and
NF-B transcription factors play a critical role for bothhigh levels of constitutive p52 and RelB DNA binding
the survival and activation of resting B cells. In miceactivity. These findings establish TRAF2 as a multi-
lacking any one of the five NF-B proteins (NF-B1,functional regulator of NF-B activation that mediates
NF-B2, RelA, RelB, c-Rel), the numbers of peripheralactivation of the canonical pathway but acts as a nega-
(particularly MZ) B cells are reduced, and B cell activa-tive regulator of the noncanonical pathway. This dual
tion by various stimuli is compromised (Gugasyan et al.,functionality explains the contrasting roles of TRAF2
2000). NF-B activation occurs via one of two majorin B cell maturation and activation.
pathways. The canonical pathway involves phosphory-
lation and subsequent degradation of I-B moleculesIntroduction
constitutively bound to cytoplasmic NF-B dimers.
These dimers, typically p50/RelA heterodimers, can bindTNF superfamily ligands (TNF-L) and receptors (TNF-R)
B DNA motifs and translocate to the nucleus followingplay pivotal roles in many facets of the immune system
I-B degradation (Li and Verma, 2002). In the noncanoni-(Locksley et al., 2001). Key mediators of TNF-R signal
cal pathway, inactive full-length NF-B2 (p100) is pro-transduction are members of the TNF-R-associated fac-
teolytically processed to its active p52 form (Ghosh andtor (TRAF) family of signaling proteins. Of the 6 mamma-
Karin, 2002; Senftleben et al., 2001) and then translo-
lian TRAFs, TRAF2 is one of the most widely utilized,
cates to the nucleus primarily in p52/RelB heterodimers
binding to the cytoplasmic domain of at least 14 different
(Coope et al., 2002; Hatada et al., 2003; Muller and Sie-
TNF-R proteins, including TNFR2, LTR, CD30, CD40, benlist, 2003). The two pathways differ in several re-
and TACI (Aggarwal, 2003). spects, including the specific dependence of the nonca-
The specific functions of TRAF2 in TNF-R signaling nonical pathway on upstream kinases IKK1 and NIK
are still emerging but involve recruitment of signaling (Senftleben et al., 2001; Yamada et al., 2000) and the
intermediates such as MEKK1 (Baud et al., 1999) and more rapid activation of the canonical pathway (Muller
the nondegradative (lysine 63) ubiquitin ligase activity and Siebenlist, 2003; Zarnegar et al., 2004).
of the TRAF2 RING finger domain (Deng et al., 2000). Both BAFF-R and CD40 efficiently activate the nonca-
The RING domain is also required for degradative (lysine nonical NF-B pathway, with BAFF-R signaling being
48) ubiquitination of TRAF2 mediated by the E3 ubiquitin responsible for most if not all of the NF-B2 processing
ligase IAP-1 (Brown et al., 2002; Li et al., 2002). Proteo- in resting B cells in vivo (Claudio et al., 2002; Kayagaki
some-dependent degradation of TRAF2 is associated et al., 2002). Mutation of the TRAF3 binding site of
with activation of a number of TNF-R molecules and may BAFF-R or the TRAF2/TRAF3 binding site of CD40 inacti-
downregulate TRAF2-dependent signaling (Duckett and vates the induction of NF-B2 processing by these re-
Thompson, 1997; Li et al., 2002). In addition, TRAF2 is ceptors (Coope et al., 2002; Kayagaki et al., 2002). While
required for the CD40-dependent degradation of TRAF3 CD40 can activate the canonical NF-B pathway, the
(Hostager et al., 2003) and may similarly influence some ability of BAFF to do so is limited (Zarnegar et al., 2004).
TRAF2 is essential for CD40-mediated activation of the
canonical pathway in primary B cells (Nguyen et al.,*Correspondence: r.brink@centenary.usyd.edu.au
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1999), but not in certain B cell lines (Hostager et al., The expression of CD19 during early B lymphopoiesis
means that extensive deletion of floxed genes is already2003).
To determine the role of TRAF2 in the regulation of B apparent at the pre-B cell stage when cd19-Cre mice are
used (Rickert et al., 1997). Because TRAF2 expression iscell physiology and NF-B activation, we have produced
conditionally TRAF2-deficient mice. TRAF2-deficient B essential for B lymphopoiesis (Yeh et al., 1997), expres-
sion of Cre from the cd19 promoter in traf2lox/lox micecells were found to possess an inherent survival advan-
tage and to accumulate preferentially in lymph nodes was considered likely to perturb early B cell develop-
ment. Thus, traf2lox/lox mice were bred instead with synge-and the splenic MZ. This phenotype mirrored that ob-
served in mice that overexpress soluble BAFF, but it neic Mx1-Cre Tg mice in which Cre expression is driven
by the type I interferon-inducible Mx1 promoter (Ku¨hnwas B cell intrinsic. TRAF2-deficient B cells displayed
constitutively high activation of the noncanonical, but et al., 1995).
Although Cre activity is typically low in unmanipulatednot the canonical, pathway of NF-B activation. Further-
more, these cells were refractory to CD40-mediated ac- Mx1-Cre Tg mice, initial analysis of traf2lox/lox  Mx1-
Cre mice revealed surprisingly high levels of traf2 genetivation of the canonical NF-B pathway and B cell prolif-
eration. In mature B cells, therefore, TRAF2 can act as inactivation in spleen and lymph nodes (LN) (Figure 2A).
By contrast, the expected low levels of Cre-mediateda positive mediator of canonical NF-B activation at the
same time as negatively regulating the noncanonical recombination were detected in thymus and BM (Figure
2A). The high level of recombination in spleen and LNpathway. This dual functionality of TRAF2 explains its
opposing functions in mediating CD40-dependent B cell was accompanied by significant splenomegaly and
lymphadenopathy in traf2lox/lox Mx1-Cre mice, whereasactivation but inhibiting mature B cell development.
the thymus and other tissues appeared grossly normal
(Figure 2B and data not shown). Analysis of lymphocyteResults
subsets in spleen and LN revealed that recombination
was particularly high in B cells but low in T cells (FiguresGeneration of traf2lox/lox Mice
2C and 2D). As a consequence, TRAF2 protein expres-To permit conditional inactivation of the traf2 locus, a
sion was almost absent from B cells but only moderatelygene-targeting construct was assembled in which exon
reduced in T cells from traf2lox/lox  Mx1-Cre mice (Fig-3 of the traf2 gene was flanked by loxP sites plus a
ures 2C and 2D). Based on Western blot data, the pro-contiguous “floxed” neor selection cassette (Figure 1A).
portion of peripheral B cells that are TRAF2 deficient inExon 3 was selected for deletion due to its proximity to
traf2lox/lox  Mx1-Cre mice is typically 80%–90% (datathe start codon and because it encodes an incomplete
not shown).number of codons (79 nucleotides) (Grech et al., 2000).
Analysis of traf2wt/lox  Mx1-Cre mice revealed thatRemoval of exon 3 from the traf2 locus therefore results
the recombination of the traf2lox locus in B cells wasin a reading frame shift and the introduction of a prema-
significantly lower in the heterozygous state (Figure 2E).ture stop codon within the exon 4-derived sequence.
Thus, the accumulation of B cells with recombinedThe targeting construct was transfected into C57BL/6
traf2lox alleles in traf2lox/lox  Mx1-Cre mice can be attrib-embryonic stem (ES) cells and homologously recom-
uted to the homozygosity of the traf2lox locus in thesebined into several ES cell clones. One of these was
mice and the resulting loss of TRAF2 protein expression.transiently transfected with a Cre expression plasmid
One explanation for this phenomenon is that the ab-in vitro. This gave rise to ES cell subclones carrying
sence of TRAF2 results in increased B cell survival, lead-either a floxed traf2 allele (traf2lox) in which neor was
ing to preferential accumulation of TRAF2-deficient Bdeleted, or an inactivated traf2 locus (traf2) lacking neor
cells in vivo. Consistent with this proposition, only lowand exon 3 (Figure 1B).
levels of traf2 gene recombination were detected inTraf2lox and traf2 ES cell subclones were used to
newly generated BM B cells (B220 HSAhi IgM) com-derive traf2wt/lox and traf2wt/ mice, respectively, which
pared to mature splenic B cells (Figure 2E). Moreover,were then backcrossed separately to generate mice ho-
B cells isolated from traf2lox/lox  Mx1-Cre mice weremozygous for the respective traf2 loci (Figure 1C).
found to have a greater in vitro survival capacity thanTraf2lox/lox mice were born at the expected Mendelian
those from control traf2lox/lox mice and expressed higherfrequencies, survived normally, and exhibited no gross
levels of the anti-apoptotic protein bcl-xL (Figure 2F).phenotypic differences from traf2wt/lox and traf2wt/wt lit-
This was true in the case of both LN B cells (Figure 2F)termates. TRAF2 protein levels were also unchanged
and splenic FO B cells (data not shown). Taken together,(Figure 1D), demonstrating that introduction of the loxP
these data indicate that TRAF2-deficient B cells arisingsites did not interfere with TRAF2 expression. In con-
from low-level Cre expression in traf2lox/lox  Mx1-Cretrast, traf2/ mice did not survive embryogenesis, and
mice preferentially accumulate in vivo due to an inherenttraf2/ neonates generated by backcrossing onto a
survival advantage.tnf/ background (Ko¨rner et al., 1997; Nguyen et al.,
1999) lacked TRAF2 expression (Figure 1D). These re-
sults therefore validated the strategy employed to gen- MZ and LN B Cell Numbers Are Selectively Increased
erate conditionally TRAF2-deficient mice. in traf2lox/lox  Mx1-Cre Mice
The fact that90% of B cells in traf2lox/loxMx1-Cre mice
are TRAF2 deficient meant that they could be analyzedTRAF2-Deficient B Cells Accumulate in traf2lox/lox 
Mx1-Cre Mice Due to Enhanced Survival Capacity without further manipulation to test the effects of TRAF2
deficiency on mature B cell development. Both the pro-Deletion of “floxed” genes in B cells is often achieved
by using cd19-Cre “knockin” mice (Rickert et al., 1997). portion and total number of B cells were increased in
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Figure 1. Targeting of the traf2 Locus in
C57BL/6 Mice
(A) Traf2 gene-targeting construct. The map
of the targeting construct indicates the three
loxP sites (open triangles) and the neor ex-
pression cassette inserted within a DNA frag-
ment from the C57BL/6 traf2 gene.
(B) Cre-mediated recombination of the tar-
geted traf2 locus. Homologous recombinant
ES cells were transiently transfected with a
Cre expression plasmid in vitro. Subclones
isolated posttransfection included those that
had lost neor and exon 3 (traf2, left) or neor
alone (traf2lox, right) and were detected by
PCR as shown.
(C) Genotyping of mice carrying modified
traf2 loci. Mice derived from traf2 and traf2lox
ES cells were backcrossed separately, and
progeny were screened by using the PCR
shown in (B). Traf2/ mice were not viable,
but traf2lox/lox mice were born at normal Men-
delian frequencies.
(D) Traf2 and traf2lox loci encode absent and
normal expression of TRAF2, respectively.
Lysates of LN B cells (left panel) or liver cells
(right panel) were analyzed for TRAF2 expres-
sion by Western blotting. Mice whose data
are shown in the right-hand panel were bred
onto a tnf/ background to facilitate postna-
tal survival of traf2/ mice.
spleens from traf2lox/lox  Mx1-Cre mice compared to than in spleen. Thus, the proportion of B cells was doubled
(Figure 3B), and total B cell numbers were increased 4-foldtraf2lox/lox and traf2wt/loxMx1-Cre littermate controls (Fig-
ures 3A and 4A). Enumeration of immature (IMM, CD21/ (Figure 4B). This expansion was accompanied by several
alterations to the B cell phenotype. Firstly, LN from35lo CD23lo), FO (CD21/35int CD23hi), and MZ (CD21/35hi
CD23lo) B cell subsets in the spleen revealed a selective traf2lox/lox  Mx1-Cre mice anomalously contained cells
displaying a MZ B cell phenotype (IgMhi IgDlo CD21/35hiexpansion of MZ B cells in traf2lox/lox  Mx1-Cre mice.
Thus, the proportion of these cells was increased 3-fold CD23lo CD1dhi) (Figure 3B and data not shown). Further-
more, the LN B cells from traf2lox/lox  Mx1-Cre mice(Figure 3A), and the total number was increased 5-fold
(Figure 4A), compared to control littermates. The identifi- expressed increased levels of CD21/35 and exhibited
increased cell size compared to control LN B cells (Fig-cation of this expanded population as MZ B cells was
confirmed by high expression of IgM and CD1d, interme- ure 3B). No expansion of peritoneal B-1 cells was ob-
served in traf2lox/lox  Mx1-Cre mice.diate expression of CD24, low IgD expression, and larger
size (Figure 3A and data not shown). Consistent with
this, immunohistological analysis revealed that the MZ B Cell Phenotype of traf2lox/lox  Mx1-Cre Mice Is Due
to Intrinsic TRAF2 Deficiencyarea of the spleen was greatly expanded in traf2lox/lox 
Mx1-Cre mice and was populated by IgMhi B cells (Figure Despite the high level of TRAF2 deletion amongst B
cells, it was possible that the B cell phenotype observed4C). In contrast, the numbers of IMM and FO B cells in
spleen were increased less than 2-fold in traf2lox/lox  in traf2lox/lox  Mx1-Cre mice was due to TRAF2 deletion
in a separate cell lineage. To investigate this possibility,Mx1-Cre mice, as were the numbers of T cells (Fig-
ure 4A). mixed BM chimeras were generated to allow TRAF2-
deficient and wild-type (wt) B cells to develop withinIn LN from traf2lox/lox  Mx1-Cre mice, the expansion
of the B cell compartment was even more extensive the same host. CD45.1 congenic wt mice were lethally
Immunity
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Figure 2. Accumulation and Enhanced Survival of TRAF2-Deficient B Cells in traf2lox/lox  Mx1-Cre Mice
(A) High, spontaneous deletion of targeted traf2 alleles in spleen and LN from traf2lox/lox  Mx1-Cre mice. Genomic DNA isolated from spleen
(SPL), LN, thymus (THY), and BM from traf2lox/lox  Mx1-Cre mice was analyzed for the presence of the unrecombined (traf2lox) or recombined
Regulation of B Cells and NF-B by TRAF2
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irradiated and reconstituted with wt (CD45.1 congenic) confirming that the abnormal phenotype of traf2lox/lox 
Mx1-Cre B cells is due to their intrinsic lack of TRAF2 ex-BM cells mixed in equal parts with BM cells from
either traf2lox/lox or traf2lox/lox  Mx1-Cre (both CD45.2) pression.
mice (Figure 5A). Following reconstitution, traf2lox/lox or
traf2lox/loxMx1-Cre-derived cells (CD45.2) were distin-
guished from wt (CD45.1) cells based on CD45.2 ex- NF-B2 Processing and p52/RelB DNA Binding
Activity Are Constitutively Highpression.
Although TRAF2 is required for lymphopoiesis (Yeh in TRAF2-Deficient B Cells
We next examined whether the absence of TRAF2 af-et al., 1997), unmanipulated traf2lox/lox  Mx1-Cre mice
display no obvious lymphopoietic deficiency (data not fected the activity of the noncanonical pathway of NF-
B activation in mature resting B cells. Western blotshown). However, in the mixed BM chimeras, traf2lox/lox
Mx1-Cre-derived cells (CD45.2) were underrepre- analysis of whole-cell lysates from freshly purified B
cells showed that NF-B2 processing was constitutivelysented in the immature B-lymphoid compartment
(B220lo HSAhi) of the BM and the immature T-lymphoid enhanced in TRAF2-deficient B cells (traf2lox/lox  Mx1-
Cre mice, Figure 7A). This enhancement was even morecompartment (CD4 CD8) of the thymus (Figure 5B).
This phenomenon became more marked over time (data marked than in B cells exposed to excess BAFF in vivo
(BAFF-Tg mice, Figure 7A). Constitutive p52 DNA bind-not shown) and was not observed in recipients of
traf2lox/lox BM (Figure 5B), suggesting that traf2lox/lox  ing activity was also elevated in TRAF2-deficient B cells,
as was that of RelB (Figure 7B). These data indicateMx1-Cre lymphoid precursors that spontaneously lose
TRAF2 expression are replaced by wt (CD45.1) precur- that the noncanonical pathway of NF-B activation is
constitutively enhanced in TRAF2-deficient B cells,sors over time. Despite this, preferential accumulation
of mature peripheral TRAF2-deficient B cells was still probably resulting in the production of active p52/RelB
heterodimers similar to those generated in response toobserved in the mixed BM chimeras. Thus, the contribu-
tion of traf2lox/lox  Mx1-Cre cells to the peripheral B cell ectopic BAFF (Hatada et al., 2003). In contrast, the activ-
ity of the canonical NF-B pathway is not constitutivelycompartment greatly exceeded their contribution to the
precursor pool (60% in LN versus 13% in BM), a phe- increased in TRAF2-deficient B cells, as indicated by
normal levels of RelA DNA binding activity (Figure 7B)nomenon not observed for traf2lox/lox  Mx1-Cre T cells
or traf2lox/lox B or T cells (Figure 5B). As a result, the and I-B expression (Figure 7D).
B:T cell ratio was specifically high among peripheral
traf2lox/lox Mx1-Cre lymphocytes in the mixed chimeras
(Figure 5C). Together, these data confirmed that the TRAF2 Is Required for CD40-Dependent Proliferation
and Canonical NF-B Activation in Mature B Cellspreferential accumulation of TRAF2-deficient B cells in
traf2lox/lox  Mx1-Cre mice is B cell intrinsic. Previous experiments have indicated an essential role
for TRAF2 in CD40-mediated activation of the canonicalThe cell-intrinsic nature of the B cell phenotype was
assessed by gating on the different B cell populations NF-B pathway and B cell proliferation (Nguyen et al.,
1999). To verify these findings, purified B cells fromshown in Figure 6A. In mice receiving wt  traf2lox/lox BM
cells, no significant difference was detected between traf2lox/lox and traf2lox/lox  Mx1-Cre mice were stimulated
in vitro with anti-CD40 ( IL-4). TRAF2-deficient B cellsCD45.2 and CD45.2 B cells with respect to CD35
expression, cell size, or development of splenic MZ B showed only weak activation of RelA (Figure 7C) and
minimal phosphorylation and degradation of I-Bcells (Figures 6B and 6C). However, in recipients given
wt  traf2lox/lox  Mx1-Cre BM cells, the CD45.2 B cells (Figure 7D), confirming the requirement for TRAF2 in
CD40-mediated activation of canonical NF-B signalingretained all of the phenotypic characteristics present in
the intact donor. This included high levels of B cell- in mature primary B cells. The requirement for TRAF2 in
CD40-dependent B cell proliferation was also confirmedspecific loxP recombination, expansion of splenic MZ
B cells, upregulated CD35 expression, and increased (Figure 7E). LPS-dependent canonical NF-B activation
and proliferation were normal in TRAF2-deficient B cellscell size (Figures 5B and 5C and data not shown). Impor-
tantly, the phenotype of CD45.2 (wt) B cells present in (Figures 7C and 7E), consistent with previous observa-
tions (Nguyen et al., 1999).the same chimeras was normal (Figures 5B and 5C),
(traf2) traf2 alleles by using the PCR outlined in Figure 1B. No recombination is observed in the absence of the Mx1-Cre transgene
(traf2lox/lox tissue).
(B) Splenomegaly and lymphadenopathy in traf2lox/lox  Mx1-Cre mice.
(C and D) B cell-specific inactivation of the traf2 locus in traf2lox/lox  Mx1-Cre mice. B and T cells were purified from (C) spleen and (D) LN
from traf2lox/lox and traf2lox/lox  Mx1-Cre mice, and genomic DNA and cell lysates were prepared. Recombination of the traf2lox allele was
analyzed by PCR (left panels) as in (A). TRAF2 protein levels were analyzed by Western blotting (right panel).
(E) Accumulation of B cells with inactivated traf2lox loci requires homozygosity and is specific for the mature B cells. (Left panel) DNA from
splenic B cells purified from traf2wt/lox  Mx1-Cre and traf2lox/lox  Mx1-Cre mice was analyzed by PCR with primers similar to those used in
(A) but which only amplified the targeted traf2lox allele. (Right panel) DNA from immature BM B cells (B220lo HSAhi IgM) and splenic B cells
from a traf2lox/lox  Mx1-Cre mouse was analyzed by PCR with the same primers used in (A).
(F) TRAF2-deficient B cells have improved survival in vitro and express elevated bcl-xL. LN cells from two traf2lox/lox and two traf2lox/lox  Mx1-
Cre mice were cultured in vitro in the absence of exogenous stimuli, and the numbers of surviving B cells were expressed as a proportion of
the number present at day 0. Points indicate data from individual mice, and lines connect the mean values. Data are representative of three
independent experiments. Lysates from freshly isolated B cells were also analyzed by Western blot for bcl-xL and -actin.
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Figure 3. Increased Frequency and Altered Phenotype of TRAF2-Deficient B Cells in traf2lox/lox  Mx1-Cre Mice
(A) Spleen cells from traf2lox/lox and traf2lox/lox  Mx1-Cre mice were stained for the indicated B cell surface molecules. Histograms in the upper
panels are gated on lymphocytes and show the increased frequency of B cells (B220) in traf2lox/lox  Mx1-Cre spleen. All other plots are gated
on B220 lymphocytes. IMM (CD21/35lo CD23lo), FO (CD21/35int CD23hi), and MZ (CD21/35hi CD23lo) B cell populations are shown, indicating
the increased frequency of MZ B cells in traf2lox/lox  Mx1-Cre spleen. All regions in the remaining profiles contain B cells of the MZ B
cell phenotype.
(B) LN B cells were analyzed as for (A) and show the increased frequency of B cells in general and the presence of MZ phenotype B cells in
traf2lox/lox  Mx1-Cre LN. Overlays in the bottom two panels show increased CD21/35 and cell size (forward light scatter 	 FSc) on LN B cells
from traf2lox/lox  Mx1-Cre mice.
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Figure 4. Specific Expansion of Splenic MZ B Cells and LN B Cells in traf2lox/lox  Mx1-Cre Mice
(A and B) Absolute numbers of cells in various B and T lymphocyte subsets were calculated for traf2lox/lox  Mx1-Cre mice and control (traf2lox/lox
and traf2wt/lox  Mx1-Cre mice) littermates (upper panels). Symbols represent data from individual mice, and columns indicate means. The
number of cells in each of the indicated subpopulations was compared between each traf2lox/lox  Mx1-Cre mouse and a simultaneously
analyzed control mouse and was expressed as a fold increase in the traf2lox/lox  Mx1-Cre animal (lower panels). Symbols represent data from
each experiment, and columns show the overall means.
(C) Histological analysis of spleen from traf2lox/lox and traf2lox/lox  Mx1-Cre mice. B cells are stained blue (B220), the marginal sinus is stained
red (MadCAM-1), and IgM B cells (dull) and plasma cells (bright) are stained green (IgM). The B cell follicle (FO) and splenic MZ (bar) are
indicated, highlighting the increased thickness of the MZ area in traf2lox/lox  Mx1-Cre mice. Note the increased frequency of extrafollicular
IgM-producing plasma cells in traf2lox/lox  Mx1-Cre mice.
NF-B2 Processing in TRAF2-Deficient B Cells this BAFF-induced processing did not exceed that pres-
ent in TRAF2-deficient B cells cultured in the absenceIs Maximal In Vivo and Not Further
Increased by BAFF or Anti-CD40 of any additional stimulus. Indeed, processing in TRAF2-
deficient B cells was not further increased by ectopicWe next tested the effects of ectopic BAFF and anti-
CD40 on NF-B2 processing in vitro. After 24 hr of stimu- BAFF (Figure 7F), indicating that TRAF2-deficient B cells
process NF-B2 at close to maximal levels in vivo.lation, BAFF significantly increased processing of p100
to p52 in control (traf2lox/lox) B cells (Figure 7F). However, Stimulation of control (traf2lox/lox) B cells with anti-CD40
Immunity
636
Figure 5. In Vivo Accumulation of TRAF2-
Deficient B Cells in traf2lox/lox  Mx1-Cre Mice
Is B Cell Intrinsic
(A) Mixed BM chimeras were generated by
reconstituting lethally irradiated CD45.1 con-
genic (C57BL/6) mice with BM from CD45.1
donors mixed in equal parts with BM from
either traf2lox/lox or traf2lox/lox  Mx1-Cre mice
(C57BL/6 	 CD45.2).
(B) Lymphocytes from the indicated subpop-
ulations were gated, and CD45.2 expression
profiles were shown. Profiles are representa-
tive of three analogous chimeras.
(C) The proportion of B cells (B220) and
T cells (CD4  CD8) in the respective
CD45.2 and CD45.2 subpopulations in pe-
ripheral lymph nodes from the indicated
mixed chimeras were derived, and the ratio
of B cells to T cells was calculated. Dots rep-
resent data from individual chimeras, and the
columns represent the means.
for 24 hr not only increased NF-B2 processing but also 2003). We therefore investigated the degradation of
TRAF3 in primary B cells and its dependence on TRAF2.led to the elevation of overall NF-B2 levels (Figure 7F).
This did not occur in traf2lox/loxMx1-Cre B cells, indicat- In control (traf2lox/lox) B cells, modest TRAF3 degrada-
tion occurred after 6 hr of stimulation with anti-CD40,ing that the signal responsible for this is TRAF2 depen-
dent. Anti-CD40-like BAFF did not further increase NF- while BAFF induced little or no TRAF3 degradation (Fig-
ure 7F). TRAF2 depletion occurred in response to anti-B2 processing in TRAF2-deficient B cells (Figure 7F).
CD40, but not BAFF (Figure 7F). TRAF3 downregulation
was not observed in TRAF2-deficient B cells, indicatingLimited TRAF3 Degradation Accompanies BAFF
and CD40 Signaling in Mature B Cells that any CD40- or BAFF-mediated TRAF3 degradation
that occurs is TRAF2 dependent. If BAFF does induceThe results obtained so far indicated that TRAF2 is a
negative regulator of NF-B2 processing in B cells. Ac- TRAF3 degradation in mature B cells in vivo, the TRAF2
dependence of this event might explain the highercording to a recent study, TRAF3 also inhibits NF-B2
processing and is degraded following treatment of B steady-state levels of TRAF3 found in TRAF2-deficient
B cells (Figures 7G).cell lines with BAFF or anti-CD40 (Liao et al., 2004).
Moreover, another report using a B cell line has shown After 24 hr in culture, TRAF3 levels were similar in
all cells regardless of stimulation or TRAF2 expressionthat TRAF3 degradation in a B cell line in response to
CD40 stimulation is TRAF2 dependent (Hostager et al., (Figure 7F). TRAF2, however, was upregulated in control
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B cells in response to both anti-CD40 and BAFF. Given an extracellular signal. CD40 signaling is not required
since NF-B2 processing and the overall B cell pheno-the negative regulatory function of TRAF2 in NF-B2 pro-
type do not differ between traf2lox/lox  Mx1-Cre andcessing, BAFF/CD40-induced upregulation of TRAF2 may
traf2lox/lox  Mx1-Cre  cd40/ mice (unpublished data).represent a negative feedback mechanism of the nonca-
In normal resting B cells, most if not all of the NF-B2nonical NF-B pathway analogous to the induction of
processing observed requires BAFF-R signaling (Clau-I-B expression by canonical NF-B signaling (Li and
dio et al., 2002; Kayagaki et al., 2002). While the involve-Verma, 2002).
ment of some other TNF-L molecule cannot be ruled out,
there are two more likely explanations. Thus, TRAF2-c-Rel Expression Is Upregulated
deficient B cells may either process NF-B2 very effi-in TRAF2-Deficient B Cells
ciently in the absence of exogenous stimuli or are highlyThe serine/threonine kinase NIK is a critical component
sensitive to BAFF signaling. Traf2lox/lox  Mx1-Cre micein the activation of NF-B2 processing (Yamada et al.,
are currently being crossed onto a baff/ background2000). Both TRAF2 and TRAF3 bind to this enzyme,
to test the requirement for BAFF in this process.making it a strong candidate as the target for the nega-
In contrast to its negative regulation of B cell develop-tive regulatory actions of these TRAF proteins. While
ment, TRAF2 was confirmed here to be essential forattempts to directly measure the expression or activity
CD40-mediated B cell proliferation (Figure 7E). This canof NIK were unsuccessful, increased levels of c-Rel were
be explained at least in part by the critical role playedobserved in TRAF2-deficient B cells (Figure 7G). Since
by TRAF2 in linking CD40 with the canonical pathwayNIK is required for the expression of c-Rel in B cells
of NF-B activation (Figures 7C and 7D). The TRAF2(Yamada et al., 2000), this result is consistent with overall
dependence of this signaling pathway in mature B cellsNIK activity being increased in B cells in the absence
confirms previous observations made by using TRAF2-of TRAF2.
deficient primary B cells (Nguyen et al., 1999). In con-
trast, a TRAF2-deficent B cell line has been shown toDiscussion
retain CD40-mediated activation of the canonical NF-
B pathway (Hostager et al., 2003), indicating that theThe severity and multiplicity of defects associated with
signaling milieu in B cell lines differs significantly fromconstitutive TRAF2 deficiency (Nguyen et al., 1999; Yeh
that of primary B cells. For instance, B cell lines mayet al., 1997) indicate that precise spatial and temporal
express higher levels of TRAF5 and may use this toablation of TRAF2 expression in vivo is required to ap-
signal NF-B activation in the absence of TRAF2, as haspreciate its various roles in normal physiology. The pro-
been described for responses to TNF (Tada et al., 2001).duction and validation of the traf2lox/lox conditional TRAF2
The novel ability of TRAF2 to mediate the canonicalgene knockout model (Figures 1 and 2) therefore repre-
pathway of NF-B activation but inhibit the noncanoni-sents an important step forward in the characterization
cal NF-B2 processing pathway is likely to stem fromof TRAF2 function. The initial studies with this model
its interactions with different pathway-specific signalingpresented here demonstrate a previously unrecognized
intermediates. Since NIK functions specifically within
role for TRAF2 in the negative regulation of mature B
the noncanonical NF-B pathway (Senftleben et al.,
cell survival, MZ B cell development, and noncanonical
2001; Yamada et al., 2000) and was originally cloned as
NF-B activation.
a TRAF2-interacting protein (Malinin et al., 1997), it is
The enhanced B cell survival, accumulation of MZ possible that TRAF2 negatively regulates NF-B2 pro-
and LN B cells, and increased B cell size and CD21/ cessing via its interaction with NIK. Interestingly, TRAF3
35 expression observed in traf2lox/lox  Mx1-Cre mice also binds NIK and was recently described to promote
(Figures 2–4) are also found in Tg mice overexpressing proteosome-dependent NIK degradation and thus limit
BAFF (Khare et al., 2000; Mackay et al., 1999). However, NF-B2 processing (Liao et al., 2004). It is possible then
this similarity is not attributable to increased BAFF ex- that TRAF2 and TRAF3 cooperatively regulate the non-
pression in traf2lox/lox  Mx1-Cre mice, since the pheno- canonical NF-B pathway via modulating NIK expres-
type is maintained in mixed BM chimeras (Figures 5 and sion and/or activity.
6). The implication is therefore that TRAF2 negatively In the study of Liao et al., BAFF or CD40 signaling
regulates signaling pathways normally triggered by was found to induce extensive degradation of TRAF3
BAFF. This was confirmed by the presence of extensive and to thereby increase NIK expression and NF-B2
NF-B2 processing and increased p52 and RelB DNA processing (Liao et al., 2004). Their proposed mecha-
binding activity in B cells from traf2lox/lox Mx1-Cre mice nism, in which signaling “derepresses” NIK rather than
(Figures 7A and 7B). Stimulation of TRAF2-deficient B directly activating it, is consistent with the observation
cells with either BAFF or anti-CD40 in vitro could not that increased TRAF3 expression inhibits rather than
increase NF-B2 processing further (Figure 7F). More- augments BAFF signaling (Xu and Shu, 2002). Our re-
over, treatment of control B cells with these same stimuli sults indicate that extensive TRAF3 degradation is not
could not increase NF-B2 processing beyond that seen required to increase NF-B2 processing (Figure 7F). In
in untreated TRAF2-deficient B cells (Figure 7F). TRAF2 this case, either preferential degradation of a specific
is therefore a powerful negative regulator of NF-B2 pool of TRAF3 (e.g., NIK-associated TRAF3) or receptor-
processing in B cells, and its absence results in close mediated sequestration of TRAF3 must be sufficient to
to maximal activation of this noncanonical NF-B activa- derepress NIK if the same pathway operates in primary
tion pathway. B cells and B cell lines.
It is unclear whether the high level of NF-B2 pro- The differences between primary B cells and the B
cell lines discussed above in terms of TRAF3 degrada-cessing observed in TRAF2-deficient B cells requires
Immunity
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ences). FITC conjugates: CD8 (clone 53-6.7), CD21/35 (7G6), CD45.2tion and CD40-mediated NF-B activation emphasize
(104), IgD (11-26c.2a); PE conjugates: CD4 (GK-1.5), CD23 (B3B4);the importance of in vivo models to understand the regu-
biotin conjugates: IgM (Bet-2), CD1d (1B1), CD5 (53-7.3), CD24 (M1/lation of signaling under physiological conditions. Fur-
69), CD35 (8C12); APC conjugate: CD45R/B220 (RA3-6B2). Biotinyl-
ther investigation of traf2lox/lox  Mx1-Cre B cells should ated mAbs were revealed with streptavidin-PerCP (BD Biosciences).
help to elucidate the specific roles played by TRAF2 in Four-color flow cytometry was performed on a dual laser FACSCali-
bur flow cytometer (BD Biosciences) and was analyzed by usingthe regulation of NF-B activation, including the signifi-
FlowJo software V.4.4.3 (Tree Star Inc.). Immature BM and maturecance of its association with NIK and its recruitment to
splenic B cells were purified by sorting on a FACSCvantage flowthe inhibitory BAFF receptor TACI (Xia et al., 2000; Yan
cytometer (BD Biosciences).et al., 2001).
Experimental Procedures Immunohistology
Spleens were snap frozen in liquid N2, and 5–7 
m sections were
Generation of traf2lox/lox Mice prepared and stained as described (Phan et al., 2003), except that
Homology fragments from a C57BL/6 traf2 genomic clone (Grech anti-IgM-FITC (BD Biosciences) was used.
et al., 2000) were inserted into a plasmid (pBS-lox-neo-lox) carrying
a “floxed” neor cassette located between two loxP sites (kind gift
Cell Purificationof Dr. Sigrid Ruuls [DNAX]). 5 homology consisted of 2.2 kb of DNA
B or T cells were isolated from single-cell suspensions of spleenspanning from 20 bp 5 of the start codon in exon 2 to an NgoMIV
and peripheral LN by negative selection with Thy1.2- or B220-Dyna-site 154 bp 3 of exon 3. This fragment also carried a loxP site
beads, respectively (Dynal), according to manufacturer’s instruc-inserted into the SpeI site located 133 bp 5 of exon 3. 3 homology
tions. In each case, the purity of negatively selected cells was deter-consisted of 9.5 kb of sequence located 3 of the NgoMIV site in
mined by flow cytometry to be 95%.intron 4 (Figure 1A). Bruce 4 C57BL/6 ES cells were transfected with
the targeting construct, and G418-resistant clones were obtained
as described (Lemckert et al., 1997). A homologous recombinant
In Vitro B Cell Survival AssayES cell clone was identified by PCR and was electroporated with
LN cells were harvested and cultured in 24-well plates (106 cells inCre expression plasmid. ES cell subclones were then screened for
0.5 ml) in RPMI medium containing 10% FCS and 50 
MloxP recombination of the targeted traf2 locus by PCR. Subclones
2-mercaptoethanol. Cells were harvested after 2, 3, and 4 days ineither lacking neor alone (traf2lox) or lacking both neor and exon 3
culture, were stained with anti-B220-APC, anti-IgD-PE, and 1 
g/ml(traf2) (Figure 1B) were used to generate mice heterozygous for the
propidium iodide (PI), and were analyzed by flow cytometry. A totaltargeted traf2 alleles (traf2wt/lox and traf2wt/) (Lemckert et al., 1997).
of 105 Calibrite beads (BD Biosciences) were added to each well
prior to harvesting. Relative numbers of live B cells (PI B220 IgD)Mice
were calculated for each sample by using the Calibrite beads as anMice were maintained on a C57BL/6 background. To generate traf2/
internal reference.and traf2lox/lox mice, traf2wt/ and traf2wt/lox animals were backcrossed
separately. In the case of traf2wt/ mice, this was done both with
and without previous breeding onto a tnf/ background (Ko¨rner et In Vitro B Cell Stimulation
al., 1997). Traf2lox/lox mice were mated with Mx1-Cre Tg mice (Ku¨hn et Small, dense splenic B cells were purified as described above, but
al., 1995) previously backcrossed for 11 generations onto a C57BL/6 with additional fractionation on a Percoll gradient and isolation from
background (Jackson Laboratories). The Mx1-Cre transgene was the 65%/80% interface (Phan et al., 2003). Purified B cells were
maintained in a heterozygous state by breeding traf2lox/lox with stimulated without further manipulation or following labeling with
traf2lox/lox  Mx1-Cre animals. BAFF-Tg mice (Mackay et al., 1999) CFSE (Phan et al., 2003). For proliferation studies, CFSE-labeled B
were kindly provided by Dr. Fabienne Mackay (Garvan Institute, cells were stimulated for 4 days with 5 
g/ml agonist anti-CD40
Sydney, Australia). CD45.1 congenic C57BL/6 mice (B6.SJL/ptprca) mAb (HM40-3; BD Biosciences) plus 10 ng/ml IL-4 (Sigma-Aldrich)
were obtained from the Animal Resources Centre (Canning Vale, or with 2.5
g/ml LPS (Sigma-Aldrich). Otherwise, purified unlabeled
Western Australia). BM chimeric mice were produced as described B cells were stimulated with 5 
g/ml anti-CD40 alone, 2.5 
g/ml
(Phan et al., 2003). Mice were bred and housed in the animal facility LPS, or 200 ng/ml soluble murine BAFF. Soluble murine BAFF, con-
of the Centenary Institute and were analyzed when they were be- sisting of an amino-terminal FLAG tag followed by amino acids
tween 2 and 4 months of age. 127–309 of murine BAFF, was expressed and purified as described
(Avery et al., 2003).
PCR
Primers used for genotyping mice with modified traf2 loci and for
detecting in vivo recombination of targeted traf2lox loci (Figure 1B) Western Blotting
Whole cells were homogenized in RIPA buffer (PBS, 0.1% SDS, 1%were 5-CCTACAGTCAAGGCTCAGTGACAA-3 and 5-GCAAGCAC
GTGGGGCAGAAGGTA-3. To avoid amplification of the wt traf2 allele NP-40, 0.5% sodium deoxycholate). Samples were fractionated by
SDS-PAGE (Nupage, Invitrogen) and were transferred to PVDF filters(Figure 2E), a separate pair of primers was used containing loxP-
derived sequences that hybridized only to the targeted traf2lox locus, and blotted with antibodies (Santa Cruz Biotechnology) directed
against the following proteins: -actin (I-19), bcl-xL (S-18), c-Rel (C),i.e., 5-TTGTACAGTTGATATACTAGTCCATCAA-3 and 5-AAGGAC
CAGCCGGTCCCTAGAACT-3. NF-B2 (K-27), TRAF2 (C-20), and TRAF3 (C-20). Antibodies against
RelA, I-B, and phospho-I-B were obtained from Transduction
Laboratories. Primary antibodies were detected with either anti-Flow Cytometry
Single-cell suspensions of murine lymphoid tissues were stained rabbit or anti-goat antisera conjugated to horseradish peroxidase
(Santa Cruz) and were visualized with electrochemiluminescence.with saturating concentrations of the following mAbs (BD Biosci-
Figure 6. Phenotype of TRAF2-Deficient B Cells in traf2lox/lox  Mx1-Cre Mice Is B Cell Intrinsic
Mixed BM chimeras were generated as described for Figure 5.
(A) Peripheral B cells (B220) derived from the two different donor BM were identified by differential CD45.2 expression (gates R1 and R2).
(B) Wt (CD45.2) and traf2-targeted (CD45.2) B cells were identified in spleens from mixed BM chimeras, and their expression of CD23 and
CD35 was shown. Expansion of MZ B cells (CD21/35hi CD23lo) was only observed in cells derived from traf2lox/lox  Mx1-Cre BM.
(C) LN cells were stained as described for (B) and showed that the generation of MZ phenotype B cells in LN (top panels), increased CD35
expression (middle panels), and increased cell size (bottom panels) are all intrinsic properties of traf2lox/lox  Mx1-Cre (TRAF2-deficient) B cells.
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Figure 7. Noncanonical NF-B Activation Is Augmented in TRAF2-Deficient B Cells, but CD40-Dependent Proliferation and Canonical NF-B
Activation Are Impaired
(A) Purified LN B cells were lysed and analyzed by Western blot for expression of NF-B2 (p100  p52), RelA, and -actin. Note the increased
processing of NF-B2 in traf2lox/lox  Mx1-Cre and BAFF-Tg (B-Tg) B cells.
(B) p52 and RelB, but not RelA, DNA binding activity is upregulated in traf2lox/lox  Mx1-Cre B cells. DNA binding activity associated with the
three NF-B subunits was assayed by ELISA of purified B cell lysates from traf2lox/lox and traf2lox/lox  Mx1-Cre mice. Background readings
were established in the presence of excess soluble wild-type (wt) NF-B oligonucleotides, and readings were obtained with the same
concentration of inactive mutant (Mut) NF-B oligonucleotides.
(C) Abrogated CD40-, but not LPS-dependent, RelA activation in TRAF2-deficient B cells. Purified B cells were incubated with the indicated
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NF-B ELISA Duckett, C.S., and Thompson, C.B. (1997). CD30-dependent degra-
dation of TRAF2: implications for negative regulation of TRAF signal-To detect active NF-B transcription factors, an ELISA-based assay
was used. Purified B cells were harvested for analysis either directly ing and the control of cell survival. Genes Dev. 11, 2810–2821.
ex vivo or following activation in vitro as described above. Cells Ghosh, S., and Karin, M. (2002). Missing pieces in the NF-B puzzle.
were lysed, and the levels of p52, RelB, and RelA NF-B transcription Cell 109, S81–S96.
factors capable of binding to a plate bound NF-B consensus se-
Grech, A., Quinn, R., Srinivasan, D., Badoux, X., and Brink, R. (2000).quence (5-GGGACTTTCC-3) were assayed by using a Trans-AM
Complete structural characterisation of the mammalian and Dro-NF-B Family Transcription Factor Assay Kit (Active Motif) as per
sophila TRAF genes: implications for TRAF evolution and the rolethe manufacturer’s instructions.
of RING finger splice variants. Mol. Immunol. 37, 721–734.
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